Key facts
- Inmedix’s last known valuation is $33.5M (Nov 2024).
- It has raised $16.3M across 3 recorded rounds; the latest was Seed Round ($720K) in Aug 2024.
- Notable investors include Keiretsu Forum, Cairi Legacy Partners, Andrew Holman, Keiretsu Capital, NW Angel — 8 tracked in total.
- Inmedix has filed 5 Form Ds with the SEC since 2021, most recently Oct 2025 ($160K sold to 4 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Inmedix
Funding rounds
3 roundsAbout Inmedix
Developer of a medical technology designed to assess autonomic nervous system function with clinical precision. The company offers an FDA-cleared, payer-reimbursed CloudHRV System that quantifies parasympathetic and sympathetic activity in minutes, enabling healthcare providers to make informed decisions for improved patient care.
- Sector
- Healthcare
- HQ
- Normandy Park, WA, United States
- Founded
- 2017
- Employees
- 6
- Website
- inmedix.com/
- Ownership
- Privately Held (backing)
Inmedix doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Inmedix shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Inmedix in its N-PORT filings yet. We sweep new filings monthly.